

# Javed Butler

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1284958/javed-butler-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

496  
papers

28,241  
citations

64  
h-index

160  
g-index

591  
ext. papers

41,707  
ext. citations

8.2  
avg, IF

7.2  
L-index

#	Paper	IF	Citations
496	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, e147-239	15.1	4318
495	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i> , <b>2013</b> , 128, e240-327	16.7	1927
494	Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 606-19	7.6	1613
493	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , <b>2017</b> , 136, e137-e161	16.7	1503
492	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1123-1133	15.1	1160
491	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1413-1424	59.2	1099
490	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 776-803	15.1	1064
489	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , <b>2021</b> , 42, 3599-3726	9.5	875
488	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1485-1513	15.1	452
487	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1451-1461	59.2	358
486	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , <b>2020</b> , 396, 819-829	40	355
485	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1883-1893	59.2	333
484	Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 351-366	15.1	333
483	Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , <b>2017</b> , 14, 238-250	14.8	322
482	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 2533-2541	27.4	322
481	Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2281-93	15.1	313
480	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1025-1029	16.2	217

479	Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1696-1706	15.1	204
478	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1085-1095	27.4	199
477	Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 519-34	3.3	195
476	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patientS with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , <b>2017</b> , 38, 1119-1127	9.5	192
475	Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 136-45	7.9	190
474	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 2251-62	27.4	188
473	Incident heart failure prediction in the elderly: the health ABC heart failure score. <i>Circulation: Heart Failure</i> , <b>2008</b> , 1, 125-33	7.6	182
472	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME <sup>2</sup> trial. <i>European Heart Journal</i> , <b>2018</b> , 39, 363-370	9.5	171
471	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1895-1904	40	162
470	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002661	7.6	156
469	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2365-2383	15.1	147
468	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of the Australian College of Cardiology, and the Heart Failure Society of Australia. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1177-1185	12.3	143
467	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 556-569	15.1	135
466	Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. <i>Archives of Internal Medicine</i> , <b>2009</b> , 169, 708-15		135
465	Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 464-72	7.9	133
464	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1279-1287	12.3	133
463	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , <b>2015</b> , 12, 220-9	14.8	129
462	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4,	6	119

461	Reframing the association and significance of co-morbidities in heart failure. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 744-58	12.3	116
460	Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 950-958	16.2	114
459	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1390-1400	12.3	111
458	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 280-288	15.1	110
457	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , <b>2019</b> , 40, 2155-2163	9.5	107
456	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 995-1006	16.2	107
455	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 704-712	15.1	106
454	Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. <i>Circulation</i> , <b>2020</b> , 142, 1028-1039	16.7	105
453	Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. <i>Circulation Research</i> , <b>2017</b> , 120, 332-340	15.7	105
452	Therapeutic targets in heart failure: refocusing on the myocardial interstitium. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2188-98	15.1	90
451	Patient selection in heart failure with preserved ejection fraction clinical trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1668-1682	15.1	89
450	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002843	7.6	84
449	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2021</b> ,	3.3	84
448	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 96-104	7.9	83
447	Utility of Patient-Reported Outcome Instruments in Heart Failure. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 165-75	7.9	82
446	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 337-349	16.7	80
445	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 1011-1019	16.2	79
444	Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002639	7.6	77

443	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. <i>International Journal of Cardiology</i> , <b>2014</b> , 172, 115-21	3.2	77
442	Validation of clinical scores for right ventricular failure prediction after implantation of continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 1595-1603	5.8	74
441	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 326-336	16.7	74
440	Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 804-813	15.1	73
439	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1270-1278	12.3	73
438	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. <i>American Heart Journal</i> , <b>2016</b> , 182, 9-20	4.9	72
437	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1512-1521	27.4	71
436	The Importance of NLRP3 Inflammasome in Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 586-93	3.3	70
435	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , <b>2019</b> , 42, 2298-2306	14.6	70
434	Adrenomedullin in heart failure: pathophysiology and therapeutic application. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 163-171	12.3	69
433	Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 868-875	3.3	64
432	Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 798-809	6.9	64
431	Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 935-944	15.1	63
430	Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 193-201	7.9	62
429	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 3370-3372	15.1	61
428	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 941-956	12.3	60
427	Hyperkalemia in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1575-89	15.1	60
426	Global left atrial failure in heart failure. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1307-1320	12.3	59

423	Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1231-9	12.3	59
424	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 1-13	7.9	58
423	Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 237-48	7.9	58
422	Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 462-463	3.3	57
421	Advance directives among hospitalized patients with heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 112-21	7.9	57
420	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 54-65	12.3	57
419	Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2018</b> , 314, H1033-H1042	5.2	57
418	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. <i>Circulation</i> , <b>2021</b> , 143, 310-321	16.7	55
417	Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 782-791	12.3	54
416	Concomitant diabetes mellitus and heart failure. <i>Current Problems in Cardiology</i> , <b>2015</b> , 40, 7-43	17.1	54
415	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 1-12	7.9	51
414	Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1591-8	15.1	50
413	Comparison of multidetector computed tomography and two-dimensional transthoracic echocardiography for left ventricular assessment in patients with heart failure. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 247-9	3	49
412	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. <i>Heart Failure Reviews</i> , <b>2016</b> , 21, 95-102	5	44
411	Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 737-42	3	44
410	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1379-1390	15.1	43
409	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2020</b> , 41, 2109-2117	9.5	42
408	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With/Without Diabetes. <i>JACC Basic To Translational Science</i> , <b>2019</b> , 4, 831-840	8.7	42

407	Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 789-90	27.4	42
406	Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 265-81	3.3	42
405	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 3029-3039	15.1	41
404	Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. <i>Atherosclerosis</i> , <b>2016</b> , 245, 181-6	3.1	41
403	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2383-2392	12.3	41
402	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1022-31	12.3	40
401	Population risk prediction models for incident heart failure: a systematic review. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 438-47	7.6	40
400	Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy. <i>JACC: CardioOncology</i> , <b>2019</b> , 1, 54-65	3.8	39
399	Management of comorbid diabetes mellitus and worsening heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 2379-80	27.4	39
398	Extent and distribution of coronary artery disease: a comparative study of invasive versus noninvasive angiography with computed angiography. <i>American Heart Journal</i> , <b>2007</b> , 153, 378-84	4.9	39
397	Association of Physical Activity or Fitness With Incident Heart Failure: A Systematic Review and Meta-Analysis. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 853-61	7.6	38
396	Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 719-29	3.3	38
395	Resting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysis. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e001364	6	37
394	High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 319-26	3.3	37
393	Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2836-2850	15.1	36
392	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	36
391	Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study. <i>JACC: Cardiovascular Imaging</i> , <b>2012</b> , 5, 131-40	8.4	36
390	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 671-680	9.5	36

389	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 999-1005	12.3	35
388	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. <i>Pharmacology &amp; Therapeutics</i> , <b>2017</b> , 176, 32-39	13.9	35
387	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , <b>2021</b> , 42, 700-710	9.5	35
386	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart Failure and Preserved Ejection Fraction (HFPEF) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , <b>2016</b> , 14, 181	11.4	35
385	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1596-1604	12.3	35
384	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 26-32	3.3	34
383	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , <b>2019</b> , 139, 1458-1460	16.7	34
382	Strategies and opportunities for drug development in heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1593-4	27.4	34
381	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 1203-1212	9.5	34
380	Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. <i>Circulation: Cardiovascular Imaging</i> , <b>2017</b> , 10,	3.9	33
379	Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 727-732	15.1	33
378	Postmarketing Adverse Events Related to the CardioMEMS HF System. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1277-1279	12.9	33
377	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57, 440-451	2.9	33
376	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. <i>American Heart Journal</i> , <b>2017</b> , 189, 177-183	4.9	32
375	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1397-1407	15.1	32
374	Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 286-296	12.3	32
373	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005875	7.6	30
372	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 931-939	7.9	30



371	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1381-1392	15.1	30
370	Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 743-744	16.2	30
369	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1072-81	12.3	30
368	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> , 144, 1284-1294	16.7	30
367	Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 528-537	7.9	29
366	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 714-722	16.2	29
365	Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 2035-6	27.4	29
364	Atrial Fibrillation and Declining Physical Performance in Older Adults: The Health, Aging, and Body Composition Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2016</b> , 9, e003525	6.4	29
363	Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 826-31	7.6	28
362	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 472-485	12.3	28
361	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e005400	7.6	28
360	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	27
359	The Cardio-Renal Interrelationship. <i>Progress in Cardiovascular Diseases</i> , <b>2017</b> , 59, 636-648	8.5	27
358	Redefining Heart Failure With a Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1761-1762	27.4	27
357	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 401-8	7.6	27
356	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006605	7.6	27
355	Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002115	7.6	27
354	Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 726-35	7.9	27

353	Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004312	7.6	26
352	Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 489-507	6.1	26
351	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	26
350	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	26
349	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3298-3309	3.7	26
348	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , <b>2014</b> , 168, 142-9	4.9	25
347	Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 183-91	7.9	25
346	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 933-941	7.9	24
345	Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. <i>Circulation</i> , <b>2020</b> , 142, 717-719	16.7	24
344	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1596-1598	15.1	23
343	Trends in characteristics of cardiovascular clinical trials 2001-2012. <i>American Heart Journal</i> , <b>2015</b> , 170, 263-72	4.9	23
342	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 75-83	3.7	23
341	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. <i>Circulation</i> , <b>2019</b> , 140, 2076-2088	16.7	23
340	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1861-1871	15.1	22
339	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005998	7.6	22
338	Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 965-72	3.7	22
337	Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 604-617 <sup>12.3</sup>	12.3	22
336	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 255-265	3.3	22

335	Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 1354-62	3.9	22
334	A Scientific Analysis of the 100 Citation Classics of Valvular Heart Disease. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 1440-1449	3	22
333	Relation of Living in a "Food Desert" to Recurrent Hospitalizations in Patients With Heart Failure. <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 291-296	3	22
332	High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 748-755	12.3	21
331	Improved Outcomes for Women on the Heart Transplant Wait List in the Modern Era. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 555-60	3.3	21
330	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , <b>2016</b> , 21, 455-62	5	21
329	Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005879	7.6	21
328	Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002797	11.6	20
327	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. <i>Circulation</i> , <b>2018</b> , 137, 1060-1073	16.7	20
326	The Right Ventricular Function After Left Ventricular Assist Device (RVF-LVAD) study: rationale and preliminary results. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2016</b> , 17, 429-37	4.1	20
325	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 813-822	7.9	20
324	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1461-1470	12.3	20
323	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 552-562	12.3	19
322	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 429-437	3.3	19
321	Effects of Exercise on ASC Methylation and IL-1 Cytokines in Heart Failure. <i>Medicine and Science in Sports and Exercise</i> , <b>2018</b> , 50, 1757-1766	1.2	19
320	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1426-1433	12.3	19
319	Relation of the metabolic syndrome to quantity of coronary atherosclerotic plaque. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 1127-30	3	19
318	Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2076-2085	15.1	19

317	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <i>International Journal of Cardiology</i> , <b>2016</b> , 216, 46-51	3.2	19
316	Empagliflozin and Major Renal Outcomes in Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1531-1533	59.2	19
315	Echocardiography in Acute Heart Failure: Current Perspectives. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 82-94.	3.3	18
314	Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , <b>2015</b> , 169, 305-14	4.9	18
313	Antecedents of self-care in adults with congenital heart defects. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 610-5	3.2	18
312	Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. <i>Heart Failure Reviews</i> , <b>2020</b> , 1	5	18
311	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 428-438	3.3	18
310	Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	18
309	Cardiovascular implications of COVID-19 versus influenza infection: a review. <i>BMC Medicine</i> , <b>2020</b> , 18, 403	11.4	18
308	Trends in prevalence of comorbidities in heart failure clinical trials. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1032-1042	12.3	18
307	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1065-1075	12.3	17
306	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 281-291	12.3	17
305	Prognostic significance of (123)I-mIBG SPECT myocardial imaging in heart failure: differences between patients with ischaemic and non-ischaemic heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2016</b> , 17, 384-90	4.1	17
304	Impact of Heart Disease on Maternal and Fetal Outcomes in Pregnant Women. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 474-80	3	17
303	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	17
302	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 142-152	15.1	17
301	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 127-136	7.9	17
300	Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1166-1187	15.1	17

299	Endpoints in Heart Failure Drug Development: History and Future. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 429-440	7.9	16
298	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1144-50	3	16
297	The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 399-407	3.3	16
296	Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 636-45	7.6	16
295	Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure. <i>Advances in Therapy</i> , <b>2015</b> , 32, 971-82	4.1	16
294	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 469-480	7.9	16
293	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. <i>Circulation</i> , <b>2020</b> , 142, 1205-1218	16.7	16
292	Cardiomyopathy and Heart Failure in Patients With HIV Infection. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 299-309	3.8	16
291	Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event. <i>Advances in Therapy</i> , <b>2020</b> , 37, 4015-4032	4.1	15
290	Trends in 30- and 90-Day Readmission Rates for Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008335	3.5	15
289	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1313-1321	12.3	15
288	Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e005629	7.6	15
287	SPECT and PET in ischemic heart failure. <i>Heart Failure Reviews</i> , <b>2017</b> , 22, 243-261	5	14
286	Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 1097-1105	3.8	14
285	Extracellular Volume and Global Longitudinal Strain Both Associate With Outcomes But Correlate Minimally. <i>JACC: Cardiovascular Imaging</i> , <b>2020</b> , 13, 2343-2354	8.4	14
284	A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. <i>American Journal of Cardiology</i> , <b>2020</b> , 130, 159-161	3	14
283	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1920-1928	14.6	14
282	Systemic inflammation and functional capacity in elderly heart failure patients. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 362-367	6.1	14

281	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 139-148	3.7	14
280	Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002444	7.6	14
279	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 760-3	12.3	14
278	Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2012469	10.4	14
277	Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. <i>European Heart Journal</i> , <b>2020</b> , 41, 3398-3401	9.5	14
276	Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. <i>Journal of Cardiovascular Pharmacology</i> , <b>2020</b> , 76, 313-320	3.1	14
275	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 141-144	11.5	14
274	Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 137-150	4.3	14
273	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 330-343	15.1	14
272	Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department: GUIDED-HF (Get With the Guidelines in Emergency Department Patients With Heart Failure). <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	13
271	The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 233-9	3.3	13
270	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006946	7.6	13
269	Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004668	5.8	13
268	Trends in Heart Failure Clinical Trials From 2001-2012. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 171-9	3.3	13
267	Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 340-6	3.3	13
266	Mobile health applications in cardiovascular research. <i>International Journal of Cardiology</i> , <b>2018</b> , 269, 265-271	3.7	13
265	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , <b>2021</b> , 143, 2370-2383	16.7	13
264	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1300-1312	12.3	13

263	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. <i>Circulation</i> , <b>2019</b> , 140, 2108-2118	16.7	13
262	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 78-86	3.3	13
261	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , <b>2020</b> , 220, 41-50	4.9	13
260	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , <b>2018</b> , 138, 1039-1053	16.7	13
259	Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 152-154	16.7	12
258	β-Adrenoreceptor Autoantibodies in Heart Failure: Physiology and Therapeutic Implications. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006155	7.6	12
257	Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 1207-1213	3	12
256	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 340-6	3	12
255	Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1247-1251	12.3	12
254	Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	12
253	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> ,	16.7	12
252	Salt, No Salt, or Less Salt for Patients With Heart Failure?. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 32-38.	4	12
251	Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	11
250	An economic evaluation of a self-care intervention in persons with heart failure and diabetes. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 730-7	3.3	11
249	Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007132	7.6	11
248	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1022-1031	12.3	11
247	Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1068-1071	12.3	11
246	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 611-616	3	11

245	Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 980-992	7.9	11
244	Association of electrocardiogram abnormalities and incident heart failure events. <i>American Heart Journal</i> , <b>2014</b> , 167, 869-75.e3	4.9	11
243	Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 593-601	3.3	11
242	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. <i>Current Heart Failure Reports</i> , <b>2017</b> , 14, 217-222	2.8	11
241	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1463-1473	4.4	11
240	Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1675-1683	12.3	10
239	Why Clinicians Should Care About the Cardiac Interstitium. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 2305-2318	2.1	10
238	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 371-380	3.3	10
237	Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014990	6	10
236	Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1012-1022	12.3	10
235	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	10
234	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 1-12	7.9	10
233	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1321-1332	15.1	10
232	Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 267-271	7.9	9
231	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1141-1150	6.7	9
230	Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 44-52	2.8	9
229	Clinical aspects of heart failure in individuals with diabetes. <i>Diabetologia</i> , <b>2019</b> , 62, 1529-1538	10.3	9
228	Exercise Capacity, Heart Failure Risk, and Mortality in Older Adults: The Health ABC Study. <i>American Journal of Preventive Medicine</i> , <b>2017</b> , 52, 144-153	6.1	9



227	Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	9
226	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2393-2398	12.3	9
225	Platelet-Derived Growth Factor in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 243, 355-369	3.2	9
224	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , <b>2019</b> , 20, 223-228	1.9	9
223	Predictors of heart failure development in type 2 diabetes: a practical approach. <i>Current Opinion in Cardiology</i> , <b>2019</b> , 34, 578-583	2.1	9
222	Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 243, 537-560	3.2	8
221	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 768-776	3.8	8
220	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1243-1262	6.7	8
219	Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 191-197	2.8	8
218	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1845-50	3	8
217	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1900-1906	3	8
216	Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1263-1269	16.2	8
215	How well do we represent ourselves: an analysis of cardiology fellowships website content. <i>Future Cardiology</i> , <b>2020</b> , 16, 281-287	1.3	8
214	Victims of Success in Failure. <i>Circulation</i> , <b>2020</b> , 142, 1129-1131	16.7	8
213	Advanced cancer is also a heart failure syndrome: a hypothesis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2021</b> , 12, 533-537	10.3	8
212	Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1250-1255	12.3	8
211	Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	8
210	Therapeutic Advances in the Management of Cardiogenic Shock. <i>American Journal of Therapeutics</i> , <b>2019</b> , 26, e234-e247	1	8

209	Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 200-208	16.2	8
208	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. <i>JAMA Cardiology</i> , <b>2020</b> ,	16.2	8
207	The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. <i>Heart Lung and Circulation</i> , <b>2021</b> , 30, 786-794	1.8	8
206	Acute Dyspnea and Decompensated Heart Failure. <i>Cardiology Clinics</i> , <b>2018</b> , 36, 63-72	2.5	8
205	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , <b>2018</b> , 137, 938-947	16.7	8
204	The Vulnerable Phase of Heart Failure. <i>American Journal of Therapeutics</i> , <b>2018</b> , 25, e456-e464	1	8
203	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 314-323	27.4	8
202	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1337-1348	15.1	8
201	Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 28-38	7.9	8
200	Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes?. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 314-315	18.1	7
199	Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2019</b> , 25, 705-713	1.9	7
198	Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Atherosclerosis). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 1972-1977	3	7
197	Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, A20-A27	1.5	7
196	Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006827	7.6	7
195	Pregnant women with heart disease: Placental characteristics and their association with fetal adverse events. <i>Acute Cardiac Care</i> , <b>2016</b> , 18, 56-64		7
194	Utility of positron emission tomography for drug development for heart failure. <i>American Heart Journal</i> , <b>2016</b> , 175, 142-52	4.9	7
193	Timely Management of New-Onset Heart Failure. <i>Circulation</i> , <b>2019</b> , 140, 621-623	16.7	7
192	Novel Endpoints for Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , <b>2017</b> , 14, 210-216	2.8	7

191	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 143-168	12.3	7
190	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 2004-2012	15.1	7
189	Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. <i>International Journal of Cardiology</i> , <b>2020</b> , 300, 245-251	3.2	7
188	Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2022-2039	15.1	7
187	Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2021</b> , 146, 36-47	3	7
186	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1529-1538	12.3	7
185	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. <i>Circulation</i> , <b>2021</b> , 144, 180-182	16.7	7
184	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , <b>2016</b> , 23, 922-31	3.4	7
183	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 185-91	12.3	7
182	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 42-51	7.9	7
181	A new educational program in heart failure drug development: the Brescia international master program. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 411-421	1.9	7
180	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 512-519	3.3	7
179	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004783	5.8	7
178	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 703-711	3.3	6
177	Low- Versus Moderate-Sodium Diet in Patients With Recent Hospitalization for Heart Failure: The PROHIBIT (Prevent Adverse Outcomes in Heart Failure by Limiting Sodium) Pilot Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006389	7.6	6
176	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1451-1461	12.3	6
175	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 270-275	3.3	6
174	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. <i>Digital Biomarkers</i> , <b>2020</b> , 4, 45-59	7.1	6

173	Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3531	3.7	6
172	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3438	3.7	6
171	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 522-531	16.2	6
170	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 336-345	7.9	6
169	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4442-4451	9.5	6
168	Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1468-1476	12.3	6
167	The Three-Decade Long Journey in Heart Failure Drug Development. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 243, 1-14	3.2	6
166	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 47-55	7.9	6
165	Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 145-153	12.3	6
164	Improving Postdischarge Outcomes in Acute Heart Failure. <i>American Journal of Therapeutics</i> , <b>2018</b> , 25, e475-e486	1	6
163	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 783-792	3.3	6
162	Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 931-956	15.1	6
161	Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	6
160	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , <b>2017</b> , 230, 301-303	3.2	5
159	The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?. <i>Circulation</i> , <b>2017</b> , 136, 1459-1461	16.7	5
158	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2517-2521	15.1	5
157	Updates on Device-Based Therapies for Patients with Heart Failure. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 53-60	2.8	5
156	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 10-16	2.8	5

155	Diagnosis and Prevention of Hypertensive Heart Failure. <i>Heart Failure Clinics</i> , <b>2019</b> , 15, 435-445	3.3	5
154	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e015752	6	5
153	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , <b>2021</b> , 64, 1583-1594	10.3	5
152	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2432-2447	15.1	5
151	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 2-19	3.3	5
150	Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1379-1381	12.3	5
149	CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	5
148	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , <b>2021</b> , 144, 1489-1499	16.7	5
147	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4455-4464	9.5	5
146	Heart failure guidelines: What's new?. <i>Trends in Cardiovascular Medicine</i> , <b>2017</b> , 27, 316-323	6.9	4
145	Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222868	3.7	4
144	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 1660-1666	3	4
143	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , <b>2018</b> , 23, 597-607	5	4
142	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 255-260	3	4
141	Current perspectives on hydralazine and nitrate therapies in heart failure. <i>Heart Failure Clinics</i> , <b>2014</b> , 10, 565-76	3.3	4
140	The Limitations of Symptom-based Heart Failure Management. <i>Cardiac Failure Review</i> , <b>2019</b> , 5, 74-77	4.2	4
139	Time is prognosis in heart failure: time-to-treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 4444	3.7	4
138	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 24, 230	12.3	4

137	Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.. <i>European Journal of Heart Failure</i> , <b>2022</b> ,	12.3	4
136	Acutely decompensated versus acute heart failure: two different entities. <i>Heart Failure Reviews</i> , <b>2020</b> , 25, 907-916	5	4
135	Clinical Associations of Vascular Stiffness, Microvascular Dysfunction, and Prevalent Cardiovascular Disease in a Black Cohort: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017018	6	4
134	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007871	7.6	4
133	Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 243-253	7.9	4
132	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008100	7.6	4
131	What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , <b>2021</b> , 42, 2373-2383	7.5	4
130	Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 1374-1381	3.3	4
129	Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium. <i>International Journal of Cardiology</i> , <b>2016</b> , 218, 136-143	3.2	4
128	Advanced cancer is also a heart failure syndrome: a hypothesis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 140-144	12.3	4
127	Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications. <i>Heart Failure Reviews</i> , <b>2021</b> , 26, 381-389	5	4
126	Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1173-1181	6.7	4
125	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. <i>JACC: Clinical Electrophysiology</i> , <b>2018</b> , 4, 944-954	4.6	4
124	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 888-895	3.3	4
123	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1798-1799	12.3	4
122	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.. <i>JACC: Heart Failure</i> , <b>2021</b> ,	7.9	4
121	Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions. <i>European Journal of Heart Failure</i> ,	12.3	4
120	Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?. <i>Current Diabetes Reports</i> , <b>2019</b> , 19, 39	5.6	3

119	Novel potassium binders as enabling therapy in heart failure. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 550-552	12.3	3
118	New treatments for hyperkalaemia: clinical use in cardiology. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, A41-A47	1.5	3
117	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1304-10	3	3
116	Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1600-1610	12.3	3
115	Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006833	7.6	3
114	Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 839-841	12.3	3
113	Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 714-717	7.9	3
112	FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i72-i72	4.3	3
111	Definitions of Stage D heart failure and outcomes among outpatients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , <b>2018</b> , 272, 250-254	3.2	3
110	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 913-921	7.9	3
109	Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense?. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 537-40	7.6	3
108	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> ,	18.1	3
107	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review.. <i>JAMA Cardiology</i> , <b>2022</b> ,	16.2	3
106	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1587-1598	15.1	3
105	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , <b>2020</b> , 43, 2684-2690	14.6	3
104	Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. <i>Circulation</i> , <b>2020</b> , 142, 790-798	16.7	3
103	Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017320	6	3
102	Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2021</b> , 145, 165-168	3	3

101	Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008410	7.6	3
100	Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities. <i>Circulation</i> , <b>2021</b> , 143, 2329-2331	16.7	3
99	Treatment patterns and clinical outcomes among patients . <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1334-1342	12.3	3
98	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 670-676	3.3	3
97	SGLT-2 inhibitors in heart failure: a new therapeutic avenue. <i>Nature Medicine</i> , <b>2019</b> , 25, 1653-1654	50.5	3
96	Therapeutic Advances in the Management of Acute Decompensated Heart Failure. <i>American Journal of Therapeutics</i> , <b>2019</b> , 26, e222-e233	1	3
95	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , <b>2021</b> , 232, 154-163	4.9	3
94	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 354-357	16.2	3
93	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	3
92	Optimal Endpoints of Acute Heart Failure Therapy. <i>American Journal of Therapeutics</i> , <b>2018</b> , 25, e465-e474		3
91	Hot Topics in Primary Care: Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus. <i>Journal of Family Practice</i> , <b>2017</b> , 66, S16-S21	0.2	3
90	Assessment of Heterogeneity in Heart Failure-Related Meta-Analyses. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007070	7.6	2
89	Orphan Drug Development in Cardiovascular Medicine. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2020</b> , 13, e006509	5.8	2
88	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 298-307	7.9	2
87	Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1426-1427	15.1	2
86	Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 307-12	3	2
85	Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy?. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 574-8	2.4	2
84	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 36, 108101	3.2	2



83	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 432-444	15.1	2
82	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2
81	Changes in inferior vena cava area represent a more sensitive metric than change in filling pressures during experimental manipulation of intravascular volume and tone. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2
80	Contextualizing Risk Among Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> ,	27.4	2
79	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008351	7.6	2
78	Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. <i>International Journal of Cardiology</i> , <b>2020</b> , 304, 116-121	3.2	2
77	Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 164-167	12.3	2
76	Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices. <i>Circulation</i> , <b>2020</b> , 142, 1974-1988	16.7	2
75	Cardiac Imaging in Dialysis Patients. <i>Kidney Medicine</i> , <b>2020</b> , 2, 629-638	2.8	2
74	Physical Activity, Inflammation, Coronary Artery Calcification, and Incident Coronary Heart Disease in African Americans: Insights From the Jackson Heart Study. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 901-911	6.4	2
73	Can we trust a smartwatch ECG? Potential and limitations. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 850-853	12.3	2
72	Prefrailty, impairment in physical function, and risk of incident heart failure among older adults. <i>Journal of the American Geriatrics Society</i> , <b>2021</b> , 69, 2486-2497	5.6	2
71	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	2
70	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , <b>2016</b> , 214, 16-8	3.2	2
69	From PARADIGM to PARAGON further evidence supporting continuous heart failure spectrum. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1536-1539	12.3	2
68	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 26-36	3.7	2
67	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 662-669	3.7	2
66	Challenges and the innovations in the care of advanced heart failure patients during COVID-19. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	2

65	Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 872-878 <sup>3.7</sup>	2
64	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1760-1763	12.3 2
63	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , <b>2021</b> , 237, 45-53	4.9 2
62	Maternal Heart Failure. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021019	6 2
61	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2775-2784	6.7 2
60	Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e007956	5.8 2
59	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARESS-HF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1472-1476	12.3 1
58	Heart failure prevention with sodium-glucose cotransporter 2 inhibitors. <i>Journal of Diabetes</i> , <b>2019</b> , 11, 601-604	3.8 1
57	Commentary: Failure predicting failure: The right ventricle after left ventricular assist device implantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2019</b> , 157, 1861-1862	1.5 1
56	Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. <i>Pregnancy Hypertension</i> , <b>2020</b> , 21, 184-190 <sup>2.6</sup>	1
55	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 1577-1581 <sup>2.1</sup>	1
54	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 618-27	3.3 1
53	Questioning the Associations of EB Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 781	16.2 1
52	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. <i>Current Heart Failure Reports</i> , <b>2017</b> , 14, 203-209	2.8 1
51	Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7 1
50	Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes. <i>Cardiac Failure Review</i> , <b>2019</b> , 5, 169-172	4.2 1
49	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7 1
48	Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7 1

47	Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO). <i>Romanian Journal of Laboratory Medicine</i> , <b>2018</b> , 26, 271-281	0.3	1
46	Prescription drug spending and hospital use among Medicare beneficiaries with heart failure. <i>Research in Social and Administrative Pharmacy</i> , <b>2020</b> , 16, 1452-1458	2.9	1
45	Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial). <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 82-86	3	1
44	Disparities in Discharge Disposition After Hospitalizations for Decompensated Heart Failure. <i>Cardiovascular Revascularization Medicine</i> , <b>2021</b> , 28, 95-97	1.6	1
43	Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). <i>American Journal of Cardiology</i> , <b>2020</b> , 136, 100-106	3	1
42	Ten lessons from the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1991-1993	12.3	1
41	Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 1885-1891	3.7	1
40	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017932	6	1
39	Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 1915-1923	3.7	1
38	Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. <i>Children</i> , <b>2021</b> , 8,	2.8	1
37	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. <i>American Heart Journal</i> , <b>2021</b> , 235, 82-96	4.9	1
36	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1477-1484	12.3	1
35	The role of sodium glucose co-transporter inhibitors in heart failure prevention. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107811	3.2	1
34	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 16-25	3.7	1
33	Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	1
32	INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 849-860	3.7	1
31	Revisiting hyperkalaemia guidelines: rebuttal. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1255	12.3	1
30	Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 1	2.5	1

29	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (From the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , <b>2021</b> , 154, 123-126	3.26	1
28	Trends in prevalence of comorbidities in heart failure clinical trials <b>2020</b> , 22, 1032		1
27	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1129-1137	15.1	1
26	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 266-275	7.9	1
25	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure.. <i>Frontiers in Physiology</i> , <b>2022</b> , 13, 857538	4.6	1
24	Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter?. <i>Current Heart Failure Reports</i> , <b>2019</b> , 16, 12-20	2.8	0
23	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 504-510	15.1	0
22	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 1-11	7.9	0
21	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e008072	5.8	0
20	Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials. <i>American Heart Journal</i> , <b>2020</b> , 230, 71-81	4.9	0
19	Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 999-1008	7.9	0
18	SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. <i>Current Cardiology Reports</i> , <b>2021</b> , 23, 59	4.2	0
17	Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 453-462	7.9	0
16	Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008147	7.6	0
15	Major Depression and Anxiety Among Patients Hospitalized With Heart Failure. <i>American Journal of Cardiology</i> , <b>2021</b> , 142, 153-155	3	0
14	Iron Deficiency in CKD Without Concomitant Anemia. <i>Kidney International Reports</i> , <b>2021</b> , 6, 2752-2762	4.1	0
13	Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 350-362	7.9	0
12	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , <b>2018</b> , 16, 123-131	2.5	

11	Leadership in cardiology. <i>European Heart Journal</i> , <b>2017</b> , 38, 2323	9.5
10	Annals for Hospitalists Inpatient Notes - Clinical Pearls-Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.. <i>Annals of Internal Medicine</i> , <b>2022</b> , 175, HO2-HO3	8
9	Sex Disparity Among Canadian Cardiologists in Academic Medicine: Differences in Scholarly Productivity and Academic Rank. <i>Cureus</i> , <b>2021</b> , 13, e18687	1.2
8	The inadequacy of cardiovascular safety reporting in breast cancer clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e24100-e24100	2.2
7	Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2021</b> , 23, 1	2.1
6	The Reply. <i>American Journal of Medicine</i> , <b>2021</b> , 134, e357	2.4
5	Biomarkers and Cancer Therapy-Related Cardiac Dysfunction. <i>Current Cardiovascular Risk Reports</i> , <b>2016</b> , 10, 1	0.9
4	How to Best Identify Elderly Individuals Who May Develop Heart Failure. <i>Current Cardiovascular Risk Reports</i> , <b>2016</b> , 10, 1	0.9
3	Standardizing the standard: reporting health status in clinical trials. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 203-204	12.3
2	Treatment of Diabetes in Patients with Heart Failure. <i>Current Cardiology Reports</i> , <b>2018</b> , 20, 97	4.2
1	Mihai Gheorghiade, MD-Life and Concepts. <i>American Journal of Therapeutics</i> , <b>2018</b> , 25, e453-e455	1